AstraZeneca's diabetes drug Xigduo approved in Europe

LONDON Wed Jan 22, 2014 2:28am EST

LONDON Jan 22 (Reuters) - AstraZeneca said European regulators had approved Xigduo for type 2 diabetes, in what was the first green light for a fixed dose combination of a SGLT2 inhibitor and metformin.

The drug combines in a twice daily tablet Forxiga, a SGLT2 inhibitor that reduces the reabsorption of excess glucose, and metformin, a standard in treating the condition.

Xigduo was developed by the alliance in diabetes therapy between the British company and Bristol-Myers Squibb, the companies said on Wednesday. AstraZeneca will take full control of the unit later this quarter.

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article